As of 2022, the number of adults aged 18 and above with obesity worldwide reached 890 million, which increases the risk of countless diseases. With China's national "Weight Management Year" in full swing, we have also made our own efforts to contribute to addressing this pressing issue.

Existing treatments have problems such as long implementation cycles, severe side effects, and high risks. Our solution not only avoids these issues, but also enables low costs and scalable production.

Our project utilizes synthetic biology to express key hydrogen sulfide metabolism enzymes, i.e., SQR and FCSD, in E. coli BL21 (DE3), and formulates them into coated oral capsules for intestinal release, which can reduce side effects.

These proteins degrade excess intestinal H₂S in obese people, restore GLP-1 pathway function, thereby promoting fat metabolism, reducing fat accumulation, and ultimately achieving fat loss.